A Biotec company in the United States believes that that they have created a groundbreaking drug that will slow down Alzheimer’s disease.
Biogen says it is now seeking approval of US authorities for the release of Aducanumab, a human monoclonal antibody, on the market. The company is set to file its application next year and also hopes to get the approval in Europe as well.
The drug could potentially slow down the onset of Alzheimer’s disease.
Biogen’s announcement however took the medical field by surprise because work on the drug had previously been abandoned after reportedly getting failed results.
The company now says that new findings showed higher doses of Aducanumab could potentially benefit patients having the early onset of Alzheimer’s.
Symptoms that could be prevented include memory loss and living skills.
Aducanumab works by targeting a protein called amyloid that forms abnormal deposits in the brains of people with Alzheimer’s.
Experts believe that clearing the brain with these toxins could eventually prevent the onset of the disease.
No new dementia drugs have been created in the past decade.
“We are hopeful about the prospect of offering patients the first therapy to reduce the clinical decline of Alzheimer’s disease,” Biogen said in a statement on BBC.
“Taking another look at Aducanumab is a positive step for all those who took part in the clinical trials and the worldwide dementia research community. As more data emerges, we hope it will spark global discussions about the next steps for delivering much-needed treatments into people’s hands,” Hilary Evans from Alzheimer’s Research UK also said.
The United Nations said that at least 50 million people around the world are living with Alzheimer’s disease. (TN)
